Skip to main
BCYC
BCYC logo

BCYC Stock Forecast & Price Target

BCYC Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 20%
Buy 50%
Hold 30%
Sell 0%
Strong Sell 0%

Bulls say

Bicycle Therapeutics has received positive feedback from key opinion leaders (KOLs) regarding its product candidate, BT1718, indicating a competitive edge over existing treatments such as Padcev, particularly in efficacy. The potential for a 40-50% increase in progression-free survival (PFS) relative to Padcev further supports the promising prospects for the company's oncology-focused pipeline. Additionally, the company's commitment to delivering safe and effective outcomes while maintaining lower system costs underscores its value proposition in the biopharmaceutical market, contributing to a favorable outlook on its stock.

Bears say

Bicycle Therapeutics PLC faces a significant negative outlook due to recent investor concerns regarding the efficacy and safety of its product candidate, BT1718, particularly in light of equivocal data that has contributed to a substantial 45% year-to-date decline in share price. Moreover, the company's shares are now trading below their cash value following updates from clinical trials, indicating a lack of investor confidence in the viability of its novel approach to drug development despite having an active molecule. Lastly, the potential for a 25% downside looms if further safety issues or poor efficacy outcomes arise, underscoring the precarious nature of its current market position.

BCYC has been analyzed by 10 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 50% recommend Buy, 30% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicycle Therapeutics Plc - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicycle Therapeutics Plc - ADR (BCYC) Forecast

Analysts have given BCYC a Buy based on their latest research and market trends.

According to 10 analysts, BCYC has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicycle Therapeutics Plc - ADR (BCYC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.